Headaches are a common symptom of a stressful lifestyle, your body not feeling well and other issues. While headaches can be dealt with easily, migraines are not so easy to handle. Migraines are a type of headache that feels like severe throbbing and pulsing sensation, almost like you are hearing your own heartbeat in your brain, usually on one side of the brain. Many people believe that migraines are not that big of a deal because you just have to deal with the pain, but that is not all migraine is, some people find it very difficult to do their daily tasks as they experience dizzying spells, nausea and extreme sensitivity to light and sound! These attacks can last hours and make it difficult for people to go about their daily lives as well. While there are medications available for migraine patients, these medications need time to take effect, so you may be in a lot of pain, but there are not many quick reliefs you can have in place other than learning the symptoms of a migraine attack and taking medication before it happens. But a new approval by the FDA may change this!

The U.S. Food and Drug Administration (FDA) has approved Symbravo, a new medicine to treat acute migraine attacks in adults. This means adults can now use Symbravo to get relief from their migraine symptoms. The FDA's decision was based on the results of three big studies, called Phase 3 trials. These trials involved over 21,000 migraine attacks, so the FDA has a lot of information about how well Symbravo works and how safe it is. The FDA only approves medicines that have been shown to be both safe and effective through a thorough testing process.

Importance of New Treatment Option

"Migraine attacks can happen suddenly and really mess up people's lives. It's estimated that over 39 million people in the U.S. alone get migraines," said Herriot Tabuteau, M.D., CEO of Axsome Therapeutics told US News. This shows how common migraines are and how important it is to have good treatments. "Symbravo gives patients and doctors a new option that can quickly stop a migraine attack, keep it away, and let people get back to their normal activities, all with just one dose." Having a medicine that can give fast and long-lasting relief from migraine pain is a big deal for millions of people. This new treatment is a real step forward in how we treat migraines.

Symbravo Trial Results, How Was It Approved

The trials took place in 3 steps, the Momentum trial study focused on people whose migraines had moderate to severe pain. The results showed that a lot more people taking Symbravo felt pain-free two hours after taking the medicine compared to those who took a placebo which is a dummy pill. Even better, many people felt relief for up to 24 and even 48 hours after just one dose. This long-lasting relief is really important for people with migraines because it means they can get back to their normal lives without worrying about the pain coming back. The study also looked at how many people were free from their worst symptom, like sensitivity to light or sound, or nausea. Symbravo worked better than the placebo in this area too.

While the intercept trial looked at people who took Symbravo when their migraine pain was still mild. Even when the pain was just starting, Symbravo was effective. The results were similar to the MOMENTUM trial, with many people getting pain relief and relief from their worst symptoms. Treating migraines early is often better because it can stop the pain from getting really bad.

And lastly the Movement trial which was to see how safe the medication is when people take it regularly. This study followed 706 people who had at least two migraines a month. The most common side effects people experienced were sleepiness and dizziness. While these side effects are important to know about, the study showed that Symbravo is generally safe for people to use on a regular basis.

In a shocking video, a woman who ordered packaged eggs sold by Eggoz from Zepto claims they were filled with plastic-made strands instead of yolk, however the brand soon quoted FSSAI's rules and issued a clarification.

Earlier this week, Shalini Singh shared an Instagram video of six eggs that appear to have yellow, thread-like strands emerging from within, suggesting that instead of slimy yolk, she found a plastic substance bursting out of the eggs after boiling them.

In the clip, the visibly upset customer is heard saying: “Until now we had only heard that fake eggs or plastic eggs were being sold in the market, but today I witnessed an example in my own home. I ordered Eggoz Everyday brand eggs from Zepto and as soon as I put them on to boil, instead of yolk, plastic started coming out from inside."

Pointing at the cracked eggs, she added, “You can see in the video yourself, plastic is coming out in the form of noodles. Each egg has the Eggoz Everyday stamp on it. Look at how plastic fake eggs are reaching our homes.

“This is what we are buying today. If they had been cooked in another way, we might not even have realized we were consuming plastic. These boiled eggs burst, and that is how we found out it was plastic. If this is the condition of such big brands today, what is even left safe to eat?"

Can Egg Yolks Be Filled With Plastic?

"Consumers need to remember that the quality and appearance of the egg mostly depend on the way they are stored and for how long they are stored. Egg quality is best maintained when they are stored in cold temperatures preferably inside refrigerators and consumed within a period of 2 to 3 days.

"When kept in room temperature, several changes take place in an egg that bring about differences in the smell, texture and appearance of the egg."

The FSSAI further suggested holding up an egg against a very bright light in a dark room to detect its age. If its fresh, the egg will display a small air gap usually at the broader (blunt) end and if its starting to age, the air cell will expand in volume.

Upon hard boiling a fresh egg, you can clearly see the indentation left behind at the top of the egg once the shell is peeled off.

When fresh eggs are boiled, the yolk normally stays in the center and is not very mobile because of the chalaza (the strings of tissue) that hold it in place. These strings break down as the egg ages (during storage or transportation). When hard boiled eggs are cut length wise, one can see that the yolk has moved off the centre.

What Did The Company Say?

"Thank you for bringing this to our attention."

They also reached out with an official clarification, stating that there is no such thing as plastic eggs and that the claims stem from common misconceptions, quoting FSSAI's guidance.

In an official statement, the brand commented: "There are no plastic eggs. Eggs are a natural agricultural product, and variations in texture or appearance may occur due to storage or temperature conditions at different stages after production. Such natural changes do not indicate the presence of artificial or plastic material and do not affect food safety."

The company also highlighted its commitment to strict farm-to-shelf quality processes, including hygienic handling, batch traceability and temperature-controlled logistics.

Denmark has become the first country in the European Union (EU) to eliminate mother-to-child transmission (EMTCT) of HIV and syphilis -- two serious, and often co-occurring, sexually transmitted infections (STIs).

The World Health Organization (WHO) validated Denmark for the EMTCT of HIV and syphilis, for low transmission rates and high coverage of prenatal testing and treatment for pregnant women from 2021 to 2024.

“The elimination of mother-to-child transmission of HIV and syphilis marks a major public health achievement for Denmark,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General.

“This milestone demonstrates that with strong political commitment and consistent investment in primary care and integrated maternal and child health services, countries can protect every pregnant woman and newborn from these diseases,” he added.

With the recognition, Denmark is now among 22 other countries and territories validated by WHO for the elimination of mother-to-child transmission of HIV, syphilis, or hepatitis B virus.

How Denmark Achieved EMTCT Of HIV And Syphilis

Elimination can be defined as testing and treating at least 95 out of every 100 pregnant women. This also includes keeping new infant infections below 50 per 100,000 births, year after year.

"Denmark has met these benchmarks through strong antenatal care, reliable data systems, and respect for women's rights. We will support Denmark as it works toward full triple elimination, when it adds hepatitis B," said Dr. Hans Henri P. Kluge, WHO Regional Director for Europe.

"This validation by WHO is a proud moment for Denmark and the result of decades of work by our health-care professionals, midwives, and public health teams to ensure that every pregnant woman receives the screening and care she needs,” added Sophie Løhde, Minister for the Interior and Health, Denmark.

Denmark has low rates of HIV and syphilis among pregnant women. While 5,950 people are living in the country with HIV, less than 0.1 percent of pregnant women are affected. With regular testing and treatment, mother-to-child transmission was reduced to zero.

Further, the systematic prenatal screening and care also reduced the cases of congenital syphilis (syphilis passed from mother to baby). In 2024, the country reported 626 cases of syphilis, more in men (524) than in women (102).

The country is now on track towards validating hepatitis B virus elimination.

The prevalence of chronic hepatitis B infection in Denmark is estimated at around 0.2–0.3 percent, mainly among migrants from endemic regions.

In October 2025, the Maldives became the first country in the world to achieve ‘triple elimination’ of mother-to-child transmission of hepatitis B, HIV, and syphilis. The country had achieved WHO validation for EMTCT of HIV and syphilis in 2019.

Global Prevalence Of HIV And syphilis

Globally, more than 39 million people were living with HIV in 2022, and over 20 million cases of syphilis were reported among women of childbearing age by 2021.

Syphilis sores create entry points for HIV, while HIV can accelerate syphilis progression.

While syphilis is curable with antibiotics, HIV is manageable but not curable.

The sexually transmitted infections are also increasing in prevalence worldwide.

More than 1 million curable STIs are acquired every day worldwide in people 15–49 years old, the majority of which are asymptomatic.

STIs have a direct impact on sexual and reproductive health through stigmatization, infertility, cancers, and pregnancy complications, and can increase the risk of HIV.

In a medical milestone, a team of US surgeons has deemed an in-utero surgery that adds stem cells to treat spina bifida -- a birth defect -- to be safe. This new type of fetal therapy does not just repair the defect but may also help heal and protect the baby’s developing spinal cord.

The Phase 1 clinical trial, published today in The Lancet and based on six babies, showed that adding a layer of human placenta-derived stem cells to standard fetal surgery can be done safely. The early safety results have prompted the US Food and Drug Administration (FDA), along with an independent monitoring board, to approve the next phase of the study.

Also Read: Priyanka Chopra, Nick Jonas Open Up About Malti’s Premature Birth And NICU Battle

Spina bifida, also known as myelomeningocele, occurs when spinal tissue fails to fuse properly during the early stages of pregnancy. The birth defect can lead to a range of lifelong cognitive, mobility, urinary, and bowel disabilities.

While surgeons have previously performed prenatal surgeries, this is the world’s first in-utero stem cell therapy for spina bifida. It is also the only clinical trial aimed at improving outcomes beyond those achieved with fetal surgery alone.

“Putting stem cells into a growing fetus was a total unknown. We are excited to report strong safety results,” said Diana Farmer, the clinical trial’s principal investigator and chair of the Department of Surgery at the University of California-Davis Health.

“It paves the way for new treatment options for children with birth defects. The future is exciting for cell and gene therapy before birth,” she added.

How The Breakthrough Fetal Surgery Was Conducted

Surgeons made a small opening in the mother’s uterus and gently positioned the fetus to expose its back and the spina bifida defect.

A small patch containing living stem cells was then placed directly over the exposed spinal cord before closing the layers of the back to allow the tissue to regenerate.

The stem cells, taken from donated placentas, are designed to protect the developing spinal cord from further damage before birth.

Also Read: Indian Drugmakers Are Gearing Up To Launch Generic Semaglutide Injections As Weight-loss Drugs Patent Expires In March

Treating Spina Bifida Before Birth

The findings from the first six babies in the trial, who were closely monitored from surgery through birth, revealed no safety concerns related to the stem cells.

After surgery, the babies experienced no infections or spinal fluid leaks. No abnormal tissue growth or tumors formed at the repair site.

All six surgeries were successful, and the stem cell patch was placed as planned in every case. All surgical wounds healed completely.

MRI scans also showed reversal of hindbrain herniation -- a condition commonly associated with spina bifida -- in all infants, an indicator of surgical success.

Hindbrain herniation in babies, often referred to as Arnold-Chiari II malformation, involves the lower part of the brain descending into the cervical spinal canal.

This can block the flow of cerebrospinal fluid, causing dangerous hydrocephalus (fluid buildup). None of the babies required a shunt for hydrocephalus before hospital discharge, the researchers said.

What Is Spina Bifida

Spina bifida affects about 1 in 2,500 births worldwide, with an estimated 1,500 to 2,000 babies diagnosed each year in the United States alone.

It is a common neural tube defect, with higher prevalence observed in regions with lower folic acid fortification. Open spina bifida specifically occurs in approximately 1 in every 2,875 births.

This surgical intervention aims to significantly improve motor function, and increase the likelihood of walking independently.

The first phase of the trial was funded by a $9 million state grant from the California Institute for Regenerative Medicine (CIRM).

The trial is now enrolling up to 35 patients in its Phase 1/2a study.

Children will be followed through age six to evaluate long-term safety and early signs of improved movement, as well as bladder and bowel function.